Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
Benzinga
OCTOBER 26, 2022
On October 23, 2022, Sumitovant Biopharma Ltd. Sumitovant), in conjunction with parent company Sumitomo Pharma Co., billion on a fully diluted basis, and a total company value of $2.9 In October 2022, Myovant's commercialization partner, Accord Healthcare, Ltd. Sumitovant Biopharma Ltd.,
Let's personalize your content